March 3 (Reuters) - China Biotech Services Holdings Ltd 8037.HK:
SEES NET LOSS ATTRIBUTABLE OF HK$180 MILLION FOR FY2024
EXPECTED RESULT DUE TO REDUCTION IN REVENUE FROM DIMINISHED DEMAND FOR COVID-19 NUCLERIC ACID TEST, OTHERS
Further company coverage: 8037.HK
((Reuters.Briefs@thomsonreuters.com;))